Summary
Androgen-receptor (AR) gene mutations have been found in clinical prostate cancer, both prior to hormonal therapy and in hormone-refractory disease that persists despite androgen-ablative therapy. Thus, mutations that are present in late-stage disease might arise prior to therapy rather than as a result of therapy. A common feature of mutations in untreated prostate cancer and in hormone-refractory prostate cancer is that the AR retains activity as a ligand-dependent transcription factor. Some AR mutations in prostate cancer show broadened ligand specificity, such that the transcription-factor activity of the AR can be stimulated not just by dihydrotestosterone (DHT) but also by estradiol and other androgen metabolites that have a low affinity for the AR. The activation of mutant AR by estrogen and weak androgens could confer on prostate cancer cells an ability to survive testicular androgen ablation by allowing activation of the AR by adrenal androgens or exogenous estrogen. Such mutations might confer an advantage even prior to androgen ablation, since prostate cancer has lower levels of 5α-reductase and, therefore, of DHT, than normal. Thus, AR mutations that occur prior to therapy may characterize a more aggressive disease. A large percentage of tumors appear to have no AR gene mutation. In tumors without an AR gene mutation, AR function might be affected via other mechanisms (e.g., AR gene amplification, which could increase the amount of AR activity at a given DHT level). Importantly, the apparent absence of AR gene mutations in the majority of early-stage tumors indicates that the role of androgen in the development of clinical prostate cancer is mediated predominantly by a normal AR gene. There are actually multiple alleles of the normal AR gene; these allelic variants differ in glutamine and glycine repeat length in the transactivation domain of the protein, and they may differ in signal-transducing activity. The glutamine and glycine repeat length may thereby modulate the effect of androgen on tumor-cell proliferation that occurs during clonal expansion.
References
Brendler CB, Follansbee AL, Isaacs JT (1985) Discrimination between normal, hyperplastic and malignant human prostatic tissues by enzymatic profiles. J Urol 133:495–501
Bussemakers MJG, Bova GS, Schoenberg MP, Hakimi JM, Barrack ER, Isaacs WB (1994) Microsatellite instability in human prostate cancer. J Urol 151:469A
Carter HB, Piantadosi S, Isaacs JT (1990) Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 143:742–746
Castagnaro M, Yandell DW, Dockhorn-Dworniczak B, Wolfe HJ, Poremba C (1993) Human androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer. Verh Dtsch Ges Pathol 77:119–123
Chamberlain NL, Driver ED, Miesfeld RL (1994) The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22:3181–3186
Cheng J, Haas M (1992) Sensitivity of detection of heterozygous point mutations in p53 cDNAs by direct PCR sequencing. PCR Methods Appl 1:199–201
Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H (1993) Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 7:1541–1550
Culig Z, Klocker H, Eberle J, Kaspar F, Hobisch A, Cronauer MV, Bartsch G (1993): DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 22:11–22
Diamond DA, Berry SJ, Jewett HJ, Eggleston JC, Coffey DS (1982) A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness. J Urol 128:729–734
Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R (1992) Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12:241–253
Elo JP, Kvist L, Leinonen K, Isomaa V, Henttu P, Lukkarinen O, Vikho P (1995) Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocrinol Metab 80:3494–3500
Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancer. Cancer Res 54:2861–2864
Gonzalez-Zulueta M, Ruppert JM, Tokino K, Tsai YC, Spruck CH III, Miyao N, Nichols PW, Hermann GG, Horn T, Steven K, Summerhayes IC, Sidransky D, Jones PA (1993) Microsatellite instability in bladder cancer. Cancer Res 53:5620–5623
Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855–4878
Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821–1828
Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA (1980) The LNCaP cell line — a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37:115–132
Irvine RA, Yu MC, Ross RK, Coetzee GA (1995) The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55:1937–1940
Kazemi-Esfarjani P, Trifiro MA, Pinsky L (1995) Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. Hum Mol Genet 4:523–527
La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77–79
Loeb LA (1994) Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 54:5059–5063
Lubahn DB, Joseph DR, Sar M, Tan J-A, Higgs HN, Larson RE, French FS, Wilson EM (1988) The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 2:1265–1275
Macke JP, Hu N, Hu S, Bailey M, King VL, Brown T, Hamer D, Nathans J (1993) Sequence variation in the androgen receptor gene is not a common determinant of male sexual orientation. Am J Hum Genet 53:844–852
Martin JB (1993) Molecular genetics of neurological disease. Science 262:674–676
Nastiuk KL, Clayton DF (1994) Seasonal and tissue-specific regulation of canary androgen receptor messenger ribonucleic acid. Endocrinology 134:640–649
Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER (1992) Androgen receptor gene mutations in prostate cancer. Proc Natl Acad Sci USA 89:6319–6323
Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, Bartsch G, Klocker H, Cato ACB (1995) Mutant androgen receptors in prostatic tumors distinguish between amino acid requirements for transactivation and ligand binding. Int J Cancer 63:544–550
Quigley CA, De Bellis A, Marschke KB, El-Awady MK, Wilson EM, French FS (1995) Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 16:272–321
Ris-Stalpers C, Verleun-Mooijman MCT, Trapman J, Brinkmann AO (1993) Threonine on amino acid position 868 in the human androgen receptor is essential for androgen binding specificity and functional activity. Biochem Biophys Res Commun 196:173–180
Ross RK, Paganini-Hill A, Henderson BE (1983) The etiology of prostate cancer: what does the epidemiology suggest? Prostate 4:333–344
Ruizeveld de Winter JA, Janssen JA, Sleddens HMEB, Verleun-Mooijman MCT, Trapman J, Brinkmann AO, Santerse AB, Schroder FH, Kwast TH van der (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144:735–746
Sadi MV, Barrack ER (1993) Image analysis of androgen receptor immunostaining in metastatic prostate cancer: heterogeneity as a predictor of response to hormonal therapy. Cancer 71:2574–2580
Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566–1572
Schoenberg MP, Tonb DC, Brown TR, Barrack ER (1993) Functional analysis of an androgen receptor gene mutation in localized human prostate cancer (abstract). Proceedings, 7th annual meeting of the Society for Basic Urologic Research, San Antonio, Texas, May 14–15
Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC, Barrack ER (1994) Microsatellite mutation (CAG24→18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 198:74–80
Silver RI, Wiley EL, Davis DL, Thigpen AE, Russell DW, McConnell JD (1994) Expression and regulation of steroid 5α-reductase 2 in prostate disease. J Urol 152:433–437
Silver RI, Wiley EL, Thigpen AE, Guileyardo JM, McConnell JD, Russell DW (1994) Cell type specific expression of steroid 5α-reductase 2. J Urol 152:438–442
Sleddens HFBM, Oostra BA, Brinkmann AO, Trapman J (1993) Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum Mol Genet 2:493
Sobue G, Doyu M, Morishima T, Mukai E, Yasuda T, Kachi T, Mitsuma T (1994) Aberrant androgen action and increased size of tandem CAG repeat in androgen receptor gene in X-linked recessive bulbospinal neuronopathy. J Neurol Sci 121:167–171
Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J (1993) Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46:759–765
Takahashi H, Furusato M, Allsbrook WC Jr, Nishii H, Wakui S, Barrett JC, Boyd J (1995) Prevalence of androgen receptor gene mutations in latent prostatic carcinomas from Japanese men. Cancer Res 55:1621–1624
Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393–1398
Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21–30
Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP (1993) Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7:1244–1255
Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E (1992) Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat shock protein interactions, and transcriptional activation. Biochemistry 31:2393–2399
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi O-P (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet 9:401–406
Wilding G (1992) The importance of steroid hormones in prostate cancer. Cancer Surv 14:113–130
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hakimi, J.M., Rondinelli, R.H., Schoenberg, M.P. et al. Androgen-receptor gene structure and function in prostate cancer. World J Urol 14, 329–337 (1996). https://doi.org/10.1007/BF00184606
Issue Date:
DOI: https://doi.org/10.1007/BF00184606